Please login to the form below

Not currently logged in
Email:
Password:

Karyopharm

This page shows the latest Karyopharm news and features for those working in and with pharma, biotech and healthcare.

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in milestone payments.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics